state Wisconsin Madison covid-19 2020 vaccine Coronavirus state Wisconsin Madison

Coronavirus lunchtime company news summary

Reading now: 645
www.pharmaceutical-technology.com

3 April 2020 Novartis, in alliance with Incyte, has announced plans to assess Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.

The planned trial will compare a combination of Jakavi and standard-of-care (SoC) therapy against SoC alone. Amgen has partnered with Adaptive Biotechnologies to discover and develop fully human neutralising antibodies targeting the SARS-CoV-2 virus that could prevent or treat Covid-19.

The alliance will combine Adaptive’s immune medicine platform with Amgen’s immunology and antibody development expertise. Read the full story here.

Vaccine development companies FluGen and Bharat Biotech have partnered with the University of Wisconsin–Madison to

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA